Merck Kgaa Dm 5 (MKGAF) 102.8500 $MKGAF Merck KGaA's Q1

New Post Public Reply Private Reply Replies (0) Message Board

Jun 9, 2016 at 10:07 AM

Merck Kgaa Dm 5 (MKGAF) 102.8500 $MKGAF

Merck KGaA's Q1 Earnings Increase Y/Y, Offers 2016 View
Zacks Equity Research - Zacks Investment Research - Fri May 20, 9:33AM CDT
Merck KGaA (MKGAF) reported first-quarter 2016 earnings of $1.50 on sales of $4 billion.
BMRN: 84.46 (+0.36), PFE: 35.42 (+0.17), BMY: 73.65 (+0.24)

Merck KGaA (MKGAF) Q1 Earnings Increased Y/Y
Zacks Equity Research - Zacks Investment Research - Thu May 19, 2:24AM CDT
Merck KGaA (MKGAF) first-quarter 2016 earnings per American Depositary Receipt (ADR) came in at $1.5.

Merck KGaA (MKGAF) Q1 Earnings: What Awaits the Stock?
Zacks Equity Research - Zacks Investment Research - Mon May 16, 7:38AM CDT
Merck KGaA (MKGAF) is scheduled to report its first-quarter 2016 earnings results on May 19.
AXON: 15.12 (+0.17), BMRN: 84.46 (+0.36), PFE: 35.42 (+0.17)

Intrexon (XON) Q1 Loss Wider than Expected, Revenues Miss
Zacks Equity Research - Zacks Investment Research - Wed May 11, 9:30AM CDT
Intrexon Corporation (XON) reported a wider-than-expected first-quarter 2016 loss of 32 cents per share.
FCSC: 1.24 (-0.02), ANIP: 55.95 (+0.15), XON: 26.00 (-0.50)

Merck KGaA's Q4 Earnings Down Y/Y, Offers 2016 Outlook
Zacks Equity Research - Zacks Investment Research - Wed Mar 09, 8:20AM CST
Merck KGaA (MKGAF) reported fourth-quarter 2015 earnings of 32 cents, down 60.2% from the year over year.
GILD: 86.73 (-0.69), PFE: 35.42 (+0.17), HZNP: 18.73 (+0.19)

Merck KGaA (MKGAF) Q4 Earnings Decline Y/Y
Zacks Equity Research - Zacks Investment Research - Tue Mar 08, 3:02AM CST
Merck KGaA (MKGAF) fourth-quarter 2015 earnings per American Depositary Receipt (ADR) came in at 32 cents.

What Awaits Merck KGaA (MKGAF) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Mar 07, 10:40AM CST
Merck KGaA (MKGAF) will be reporting its fourth-quarter 2015 earnings results on Mar 8.
BDSI: 2.86 (-0.06), BMRN: 84.46 (+0.36), PFE: 35.42 (+0.17)

Pfizer, Merck KGaA, Verastem Ovarian Cancer Study Tie-Up
Zacks Equity Research - Zacks Investment Research - Fri Mar 04, 3:00PM CST
Pfizer (PFE), Merck KGaA and Verastem tie up to evaluate avelumab in combination with VS-6063 for the treatment of ovarian cancer.
VSTM: 1.57 (-0.03), SNDX: 14.00 (-0.24), PFE: 35.42 (+0.17)

Pfizer & Merck KGaA Partner with Syndax for Ovarian Cancer
Zacks Equity Research - Zacks Investment Research - Tue Jan 05, 12:50PM CST
Pfizer (PFE) and Merck KGaA (MKGAF) teamed up with Syndax Pharmaceuticals to evaluate the avelumab/entinostat combination for ovarian cancer.
PFE: 35.42 (+0.17), HZNP: 18.73 (+0.19), ARNA: 2.14 (-0.01)

Pfizer/Merck KGaA Start Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Wed Dec 23, 3:30PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of ovarian cancer and urothelial cancer.
ACHN: 9.73 (+0.12), PFE: 35.42 (+0.17), ANIK: 48.91 (+0.19)

Pfizer/Merck KGaA Begin Two Phase III Studies on Avelumab
Zacks Equity Research - Zacks Investment Research - Thu Dec 10, 2:20PM CST
Pfizer (PFE) and Merck KGaA announced the initiation of two phase III studies on avelumab for the treatment of advanced or metastatic gastric/gastro-esophageal junction cancers.
ACHN: 9.73 (+0.12), PFE: 35.42 (+0.17), ANIK: 48.91 (+0.19)

Merck KGaA-Pfizer's Avelumab May Get Orphan Status in EU
Zacks Equity Research - Zacks Investment Research - Fri Nov 27, 1:40PM CST
Merck KGaA (MKGAF) and Pfizer (PFE) announced that the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion for immunotherapy candidate, avelumab.
MRK: 57.71 (+0.09), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

Pfizer's (PFE) Xalkori Positive in Another Phase III Study
Arpita Dutt - Zacks Investment Research - Thu Nov 19, 1:52PM CST
Pfizer's (PFE) Xalkori scored in another phase III study. The company also got breakthrough therapy status for avelumab.
AGN: 250.44 (+0.49), PFE: 35.42 (+0.17), LLY: 75.46 (+0.55)

Intrexon (XON) Reports Wider-than-Expected Loss in Q3
Zacks Equity Research - Zacks Investment Research - Tue Nov 10, 9:30AM CST
Intrexon Corporation (XON) reported third-quarter 2015 loss of 34 cents per share.
XON: 26.00 (-0.50), BXLT: 46.02 (-0.18), ANIK: 48.91 (+0.19)

Merck KGaA/Pfizer's Avelumab Gets Fast Track Status
Zacks Equity Research - Zacks Investment Research - Thu Oct 08, 1:50PM CDT
Merck KGaA (MKGAF) and Pfizer announced that avelumab received fast track status from the FDA for metastatic merkel cell carcinoma.
MRK: 57.71 (+0.09), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

Merck KGaA's Pipeline on Track, Updates Key R&D Projects
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:40PM CDT
Merck KGaA (MKGAF) provided an update regarding the stages of development of its key immuno-oncology and oncology pipeline candidates.
ENDP: 18.10 (+0.38), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

BioMarin (BMRN) to Acquire Rights to Phenylketonuria Drugs
Zacks Equity Research - Zacks Investment Research - Fri Oct 02, 3:10PM CDT
BioMarin (BMRN) announced that it has acquired all global rights to Kuvan and pegvaliase from Merck Serono, a division of Merck KGaA (MKGAF).
BMRN: 84.46 (+0.36), NVET: 4.27 (+0.26), REGN: 389.77 (+0.80)

Roche's Primary Progressive MS Drug Positive in Phase III
Zacks Equity Research - Zacks Investment Research - Mon Sep 28, 3:20PM CDT
Roche (RHHBY) announced encouraging results from the phase III ORATORIO study on ocrelizumab for primary progressive multiple sclerosis.
PFE: 35.42 (+0.17), LLY: 75.46 (+0.55), NVS: 81.03 (-0.36)

Merck KGaA Continues Restructuring Efforts, Growth in Focus
Zacks Equity Research - Zacks Investment Research - Wed Sep 16, 8:40AM CDT
Merck KGaA (MKGAF) continues with its efforts to simplify the company's organizational structure and focus on the growth trajectory of the Healthcare business.
VRX: 24.67 (+0.75), PFE: 35.42 (+0.17), CORT: 5.63 (-0.01)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

HERVolution's HERV-K Antigens: A Cancer Breakthrough?

Digging into HERVolution's Game-Changing Data Picture HERVolution in the spotlight, rolling out data that could shake up our approach to cancer immunotherapy. The big headline? HERV-K antigens might just be the whistle-blower we've been looking for to get the immune system off the bench and onto the field. How's that for a kick in the conventional wisdom of cancer...

Insurify's AI Gateway: A New Era in Insurance Shopping

Insurify's Game-Changing AI Agent Gateway In the insurance world, Insurify's latest move feels like a bull charging through a ticker tape parade. This Cambridge-based pioneer unveiled its AI Agent Gateway, aiming to put consumers back in the driver's seat. By connecting digital assistant agents to its platform, Insurify's making insurance shopping a bit less like pulling...

Amgen Q3 2026 Results: What Investors Should Know

Amgen Prepares to Reveal Third Quarter 2026 Financials If there's one thing I've learned about investing, it's that the devil's in the details, and Amgen's (NASDAQ:AMGN) upcoming webcast for its third quarter 2026 financial results is exactly the kind of detail that sets market-watchers' hearts racing. Scheduled for November 3, just after the U.S. markets close, this is...

Oracle's Bold Vision: Targeting $225B Revenue by 2030

Oracle Lays Down a Bold Gauntlet Oracle Corporation (NYSE: ORCL) sure knows how to draw the spotlight. With their recent Investor Day in Vegas, they've laid out ambitions that could make even the most seasoned Wall Streeter spit out their coffee. Who would've thought they'd be betting on a whopping $225 billion in revenue by FY30? That's supposed to be a more than 35%...

Yeastar's AI Innovations Shine at Yeahs Awards 2026

Award Recap: The Best of Yeastar’s Yeahs 2026 Blasting out of the gates here with some hefty recognition at the Yeahs Awards 2026—Yeastar is slinging accolades like confetti at a wedding. What’s the deal? It’s all about their partners and their slick moves in Unified Communications (UC). These tech whizzes are racking up milestones in AI, cloud services, and...

Unlocking Geothermal's Heat Potential in Europe

An Overlooked Powerhouse: Geothermal Heat in Industry These days, it feels like everyone’s got their head in the clouds about renewables—think wind and solar. But under the surface, literally, is geothermal energy, waiting to make a play in Europe’s industrial sector. Project InnerSpace and Future Cleantech Architects are spotlighting a sleeping giant with their...

ASE Technology Shows Strong Growth in Q3 Financials

Taipei's Semiconductor Giant Surging Ahead You wanna talk about growth? ASE Technology Holding Co. just posted some fire results for their third quarter of 2026. Revenues screaming to NT$244,161 million, that's a tidy 44.8% jump year-over-year, and even 27.8% more than they grabbed last quarter. Call me old school, but I do love when a company's financials tell a tale of...

Milestone's 2026 LawHER Scholars: A Step Forward for Equity

A Significant Step for Women in Law Now, here’s a twist in the legal world that actually shakes things up in a good way. Milestone and Scholarship America just rolled out the red carpet for some promising female law students. We're looking at serious cash on the table: a top prize of $25,000 plus a couple more at $10,000 each, earmarked for women stepping into a...

ESENTIA Lifts EBITDA, Reduces Debt, Eyes Expansion

ESENTIA Flexes Financial Muscles: What's the Deal? Walk with me through the gritty world of financials, and you’ll see that ESENTIA’s latest figures are a mixed bag with a tantalizing upside. We're talking about adjusted EBITDA ticking up to a cool $86 million in the third quarter of '26, a 1.3% lift from last year. Not too shabby, eh? Especially when you're grappling...

AI Identity Fraud Forces New Screening Tactics in Hiring

AI and Identity Fraud: A New Hiring Challenge Piling up futuristic gadgets and tech has made hiring more like a cat and mouse game lately. You'd think checking someone's background would shut the case, but tech-savvy fraudsters have other plans. Employers are up against AI-generated shenanigans and identity theft that are making the business of verifying who exactly...